Education
About Us
Working with TipRanks
Follow Us
Astrazeneca Plc (DE:ZEGA)
FRANKFURT:ZEGA
ZEGA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€57.50 - €79.50
Previous CloseN/A
Volume0.00
Average Volume (3M)28.00
Market Cap
$188.20B
Enterprise Value€459.81B
Total Cash (Recent Filing)$5.39B
Total Debt (Recent Filing)$31.29B
Price to Earnings (P/E)26.4
Beta0.67
Next Earnings
Jul 29, 2025EPS Estimate
0.95Last Dividend Ex-Date
Feb 21, 2025Dividend Yield3%
Share Statistics
EPS (TTM)1.07
Shares Outstanding3,101,316,000
10 Day Avg. Volume3
30 Day Avg. Volume28
Financial Highlights & Ratios
PEG Ratio-4.82
Price to Book (P/B)10.57
Price to Sales (P/S)0.00
P/FCF Ratio47.47
Enterprise Value/Market Cap2.44
Enterprise Value/Revenue2.20
Enterprise Value/Gross Profit10.27
Enterprise Value/Ebitda7.18
Forecast
1Y Price Target
$75.81Price Target Upside22.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
AstraZeneca News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsDESTINY-Breast09 demonstrated a highly statistically significant and clinically meaningful improvement in PFS for Enhertu + pertuzumab vs the control arm standard of care in patients with 1L HER2+ metastatic breast cancer.
Financial PerformanceCore EPS of $2.49 was a 10% beat versus consensus, partially offsetting the Total Product Sales miss.
New Product PotentialMore recently launched products including Ultomiris, Enhertu, Saphnelo, Tezspire, and Beyfortus collectively have $15B+ in sales potential to AZN in 2030.
Bears Say
Discontinued TrialsThe discontinuation of the CAPItello-280 Ph 3 trial evaluating Truqap in patients with metastatic castration-resistant prostate cancer was announced.
Product RevenueThe company reported product revenues of $12,875bn, below consensus estimates of $13,145bn by approximately 2%.
Regulatory And Compliance RisksCurrent investor concerns mainly revolve around risks to the China business due to alleged improper practices by former employees.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
5.68%
Mutual Funds
5.90% Other Institutional Investors
87.49% Public Companies and Individual Investors
ZEGA FAQ
What was Astrazeneca Plc’s price range in the past 12 months?
Astrazeneca Plc lowest stock price was €57.50 and its highest was €79.50 in the past 12 months.
What is Astrazeneca Plc’s market cap?
Astrazeneca Plc’s market cap is $188.20B.
When is Astrazeneca Plc’s upcoming earnings report date?
Astrazeneca Plc’s upcoming earnings report date is Jul 29, 2025 which is in 34 days.
How were Astrazeneca Plc’s earnings last quarter?
Astrazeneca Plc released its earnings results on Apr 29, 2025. The company reported €1.074 earnings per share for the quarter, beating the consensus estimate of €0.963 by €0.111.
Is Astrazeneca Plc overvalued?
According to Wall Street analysts Astrazeneca Plc’s price is currently Undervalued.
Does Astrazeneca Plc pay dividends?
Astrazeneca Plc pays a Semiannually dividend of €1.321 which represents an annual dividend yield of 3%. See more information on Astrazeneca Plc dividends here
What is Astrazeneca Plc’s EPS estimate?
Astrazeneca Plc’s EPS estimate is 0.95.
How many shares outstanding does Astrazeneca Plc have?
Astrazeneca Plc has 3,101,316,000 shares outstanding.
What happened to Astrazeneca Plc’s price movement after its last earnings report?
Astrazeneca Plc reported an EPS of €1.074 in its last earnings report, beating expectations of €0.963. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Astrazeneca Plc?
Currently, no hedge funds are holding shares in DE:ZEGA
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$75.81 (22.27% Upside)
$75.81 (22.27% Upside)
Blogger Sentiment
Bullish
DE:ZEGA Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.16%
12-Months-Change
Fundamentals
Return on Equity
19.81%
Trailing 12-Months
Asset Growth
3.87%
Trailing 12-Months
Company Description
Astrazeneca Plc
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
ZEGA Company Deck
ZEGA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong start to 2025 with significant revenue and EPS growth, driven by pipeline advancements and strategic global manufacturing. However, challenges such as Medicare Part D redesign and headwinds in China and Soliris revenue present areas of concern.Read More>ZEGA Stock 12 Month Forecast
Average Price Target
€75.81
▲(22.27%Upside)